Loading…

ZoetisZTSCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

World's largest animal-health company, selling vaccines, medicines and diagnostics for pets and livestock.

Momentum strong 79
Mkt cap
$34.8B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$384M
20-day average traded
Fwd P/E
13.8×
forward earnings
ROIC−WACC
+17.7 pp
WACC 7.8%
Hurdle
-10 pp
Req g minus delivered
Official | Implied
BBB+ / A-
agencies · bond market
Next earnings
90 days
16 Feb 2027
Close · USD$85.57
1D+2.5%
1W+3.6%
1M+6.9%
3M+14.1%
6M+7.3%
YTD-31.4%
1Y-27.4%
ATR %3.0%
Beta0.62
52w lowhigh35.1% off high

What Zoetis does

World's largest animal-health company, selling vaccines, medicines and diagnostics for pets and livestock.

Sells mostly through veterinarians and distributors, with pet medicines for itch, pain and parasites making up the larger share and livestock products steadier. A few big brands, such as Apoquel and Cytopoint for dog skin allergies, carry much of it. Pfizer floated it in 2013.

Products and services

  • Companion-animal medicines (parasiticides, pain)
  • Livestock vaccines
  • Diagnostics
  • Dermatology (Apoquel, Cytopoint)

Customers

  • Veterinarians
  • Livestock producers
  • Pet owners (via vets)

Where it sits in the supply chain

  • Animal health
  • Veterinary pharmaceuticals…
  • Companion animal & livestock

What could go right

  • Rising pet ownership and companion-animal spend
  • Emerging-market livestock protein demand

What could go wrong

  • Generic competition in parasiticides
  • Livestock disease-outbreak/trade disruption risk

Moat: wide (scale, brand, distribution). Largest R&D and sales scale in animal health with entrenched veterinary relationships.

Headquarters: Parsippany, New Jersey, United States · Founded: 1952 · Employees: 14,500

Named competitors

Zoetis at a glance

Size Zoetis (ZTS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $34.8B, the 326th largest of 3,085 United States companies the cockpit tracks. Shares closed at $85.57 on 18 Nov 2026.

Performance Over six months the shares gained 7.3%, against +13.3% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 21 in its peer set.

Growth Revenue grew 1.2% over the last twelve months (peer median +16.4%); the operating margin is 37.4% (peer median 17.8%).

Valuation It trades at 13.8× forward earnings against a peer median of 19.8× (5th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -10 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 17.7 points above its cost of capital (7.8% WACC).

Credit Zoetis has 11 bonds outstanding ($9.15B), rated BBB+ by the agencies and trading like A- at a weighted spread of 84 bp.

Short interest Short interest is 4.1% of the free float (30 Oct 2026).

Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011012021 May 202621 Aug 202618 Nov 2026Peer median 115ZTS 107
Six months, rebased to 100: Zoetis against the median of its 20 peers (local-currency closes).

Zoetis financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$9.51B$9.47B$9.26B$8.54B$8.08B
Revenue growth—+2%+8%+6%—
Gross profit$6.66B$6.67B$6.40B$5.83B$5.48B
EBITDA$4.03B$4.08B$3.89B$3.56B$3.39B
Net income$2.49B$2.67B$2.49B$2.34B$2.11B
Free cash flow$2.28B$2.28B$2.30B$1.62B$1.33B
Capital expenditure$495M$621M$655M$732M$586M
Total debt$9.24B$9.30B$6.80B$6.81B$8.13B

Quarterly statements and history in the cockpit →

Zoetis competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-10%0%+10%+20%BIIB45034568DIVISLABRPRXHLN4578SDZROIV1276688235INSM3692SUNPHARMAINCYGALDVTRSSIGBAYNALNYZTS6-month return →1-month return →
Up and to the right = strong over both horizons. Zoetis is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%20×40×60×BIIB4503DIVISLABRPRXSDZ12766882353692SUNPHARMAINCYGALDVTRSSIGALNYZTSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zoetis is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%+80%0%25%50%75%BIIB45034568DIVISLABRPRXHLN4578688235SUNPHARMAINCYGALDSIGALNYZTSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Zoetis is the large dot.

Zoetis competitors and peer comparison

Head to head with its named competitors (ZTS vs ELAN vs MRK vs IDXX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Zoetis ZTS$34.8B+7%+1%37%13.8×-2.9%
Elanco Animal Health ELAN$13.3B+28%+12%8%21.5×32.9%
Merck & MRK$340B+23%+5%18%16.4×8.3%
Idexx Laboratories IDXX$55.0B+26%+12%32%42.9×29.0%

How Zoetis compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zoetis against its 20 peers (data as of 18 Nov 2026)
MeasureZTSPeer medianRank in peer set
1-month return+6.9%+5.0%10th highest of 21
6-month return+7.3%+13.3%8th lowest of 21
Distance from 52-week high-35.1%-8.7%4th lowest of 21
Revenue growth (TTM)+1.2%+16.4%3rd lowest of 21
Operating margin37.4%17.8%3rd highest of 21
Forward P/E13.8×19.8×5th cheapest of 19
Growth the price implies (Req g, 7 yrs)-2.9%10.1%2nd least demanding of 18
Growth delivered (Del g)+7.2%+10.8%8th lowest of 18
Hurdle (Req g minus delivered)-10.1 pp+3.0 pp4th least demanding of 18
ROIC minus cost of capital+17.7 pp+4.4 pp6th highest of 21
EV / EBITDA10.5×21.0×5th cheapest of 18
Net debt / EBITDA1.9×0.2×7th most indebted of 18
Bond spread84 bp100 bp2nd tightest of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zoetis ZTSUnited States$34.8B+7%+1%37%13.8×-2.9%+7.2%
Biogen BIIBUnited States$37.2B+34%+2%17%17.1×10.1%-5.1%
Astellas Pharma 4503.TJapan$31.4B+17%+19%23%12.9×-9.0%+11.4%
Daiichi Sankyo 4568.TJapan$31.4B+8%+17%13%18.4×7.6%+17.1%
Divi's Laboratories DIVISLAB.NSIndia$31.3B+60%+22%34%73.5×47.1%+8.9%
Royalty Pharma RPRXUnited States$39.4B+29%+11%66%11.5×10.8%+2.3%
Haleon HLN.LUnited Kingdom$39.6B0%+1%23%16.4×5.2%+2.2%
Otsuka Hldgs 4578.TJapan$39.9B+9%+11%18%16.8×1.6%+11.7%
Sandoz SDZ.SWSwitzerland$41.7B+26%+1%15%24.5×7.5%+0.4%
Roivant Sciences ROIVUnited States$28.1B+20%+102%-3,234%n/an/an/a
Jiangsu Hengrui Pharmaceuticals 1276.HKHong Kong$44.9B-24%+11%27%28.1×9.1%+2.0%
BeOne Medicines 688235.SSChina$45.5B+9%+25%18%59.7×19.1%+79.3%
Insmed INSMUnited States$26.3B+3%+240%-42%n/an/an/a
Hansoh Pharma 3692.HKHong Kong$25.3B-3%+25%38%25.8×7.9%+10.8%
Sun Pharmaceutical Industries SUNPHARMA.NSIndia$48.0B-1%+12%23%36.0×28.7%+11.7%
Incyte INCYUnited States$24.0B+21%+25%12%15.1×14.2%+14.0%
Galderma GALD.SWSwitzerland$51.9B+18%+16%19%45.7×18.0%+6.4%
Viatris VTRSUnited States$23.3B+23%+5%11%7.5×11.2%+3.7%
Sigma Healthcare SIG.AXAustralia$22.4B+2%+209%9%38.4×28.9%+26.1%
Bayer BAYN.DEGermany$60.3B+48%0%13%12.3×n/an/a
Alnylam Pharmaceuticals ALNYUnited States$20.0B-50%+56%20%21.2×0.5%+49.8%

Zoetis bonds and credit

Zoetis has 11 bonds outstanding with $9.15B face value. The agencies rate it BBB+; its bonds trade like A-. Weighted yield 5.73%, a spread of 84 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Zoetis's main competitors?
Named competitors: Elanco Animal Health (ELAN), Merck Animal Health (MRK), Idexx Laboratories (IDXX), Boehringer Ingelheim (private or unlisted). The cockpit's measured peer set (industry) also includes Biogen (BIIB), Astellas Pharma (4503.T), Daiichi Sankyo (4568.T), Divi's Laboratories (DIVISLAB.NS), Royalty Pharma (RPRX), Haleon (HLN.L).
Is Zoetis expensive compared with its peers?
On forward p/e it trades at 13.8× against a peer median of 19.8×, 5th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -10 pp: the price already allows for a slowdown.
How has Zoetis stock performed?
Over six months to 18 Nov 2026 the shares returned +7.3% against +13.3% for the median peer; over one year -27.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.